Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database

Objective Evaluate the overall survival (OS) of patients with multiple myeloma (MM) at different treatment stages in France. Methods This retrospective observational cohort study used data from the French National Health Insurance database to study patients with MM (diagnosis 2013–2019). Patient out...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of haematology 2023-07, Vol.111 (1), p.125-134
Hauptverfasser: Leleu, Xavier, Gorsh, Boris, Bessou, Antoine, Paka, Prani, De Nascimento, Julie, Colin, Xavier, Landi, Suzanne, Wang, Peter Feng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective Evaluate the overall survival (OS) of patients with multiple myeloma (MM) at different treatment stages in France. Methods This retrospective observational cohort study used data from the French National Health Insurance database to study patients with MM (diagnosis 2013–2019). Patient outcomes included OS (all‐cause mortality), time‐to‐next treatment (TTNT), and duration of therapy (DoT) from initial diagnosis, the start of different lines of therapy (LOTs), triple‐class exposure (TCE), and subsequent treatment following TCE. The Kaplan–Meier method analyzed “time‐to‐event” data. Results From diagnosis, death rates increased from 1% at 1 month to 24% at 2 years; median OS was 63.8 months (N = 14 309). Median OS from the start of LOTs declined from 61.0 months (LOT1) to 14.8 months (LOT4). Median OS from TCE start was 14.7 months. There was a large variation in TTNT within LOTs (e.g., LOT1: bortezomib + lenalidomide: TTNT = 26.4 months, OS = 61.7 months; lenalidomide: TTNT = 20.0 months, OS = 39.6 months); DoT was similar for LOT1 and LOT2, then progressively declined at LOT4. Patients with stem cell transplant, younger age, and less comorbidity had better survival outcomes. Conclusions Patients with MM face a poor prognosis after relapse to multiple LOTs and TCE, demonstrating a worsening of survival outcomes. Access to novel therapies may improve outcomes.
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.13976